Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pan-Asia United States PrEvention of Sudden Cardiac Death Catheter Ablation Trial (PAUSE-SCD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02848781
Recruitment Status : Recruiting
First Posted : July 28, 2016
Last Update Posted : June 13, 2019
Sponsor:
Collaborator:
Abbott Medical Devices
Information provided by (Responsible Party):
University of Chicago

Brief Summary:
The current standard of care for ventricular tachycardia (VT) includes the use of medicine called anti-arrhythmic drugs (AADs) and Implantable Cardioverter Defibrillator (ICD) therapy. These treatments are used to terminate the irregular heartbeats and bring the heart back to a normal rhythm. Catheter ablation is a procedure used to eliminate (damage) the heart cells causing the arrhythmia. Patients eligible for this may benefit from an ablation procedure in addition to an ICD to treat their VT condition or risk of developing VT. This study aims to show that treating VT with catheter ablation, if performed preemptively at the time of ICD implantation, will reduce subsequent recurrent VT, ICD shocks, and lead to improved survival.

Condition or disease Intervention/treatment Phase
Ventricular Tachycardia (VT) Device: Implantable Cardioverter Defibrillator (ICD) Procedure: Catheter Ablation Not Applicable

Detailed Description:

Subjects who meet inclusion/exclusion criteria will be entered into the randomized trial. Randomization will be 1:1 between control group and ablation group. Those randomized to the control group will receive ICD therapy and routine drug therapy (including antiarrhythmic drugs as indicated). Subjects randomized to the ablation group will receive ablation therapy plus ICD for ventricular tachycardia. Patients that refuse ICD therapy and undergo ablation only will be enrolled in a prospective registry.

Follow-up will be performed prior to hospital discharge for incision check and device interrogation as is standard of care. In addition, routine device and clinical follow-up will be scheduled at 1, 3, 6, 12, 18, and 24 months. Electrocardiography (ECG) will be performed pre-implant and prior to hospital discharge. Echocardiography (TTE) will be performed pre-implant and at 12 and 24 months.

Patients that refuse ICD implantation will not be randomized and will be approached for inclusion into a registry if they undergo catheter ablation without an ICD. Basic demographics and medical history will be collected from registry subjects upon enrollment. Registry subjects will receive follow-up for routine clinical care every 6 months to check on their overall status.

120 subjects will be randomized. An additional 60 subjects will enrolled into the registry.

As of the time protocol revision C changes were made (07Nov2016), 33 subjects have been randomized. There has not been any preliminary or interim analysis of any data at this point. The study-sponsor has not had any access to any clinical follow-up for the patients enrolled to date.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 180 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: PAUSE-SCD: Pan-Asia United States PrEvention of Sudden Cardiac Death Catheter Ablation Trial
Actual Study Start Date : November 30, 2015
Estimated Primary Completion Date : February 2021
Estimated Study Completion Date : February 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: ICD with Ablation
Patient will receive an implantable cardioverter defibrillator (ICD) with catheter ablation and standard medical management.
Device: Implantable Cardioverter Defibrillator (ICD)
An ICD is a battery-powered device placed under the skin that keeps track of heart rate. Thin wires connect the ICD to the heart. If an abnormal heart rhythm is detected, the device will deliver an electric shock to restore a normal heartbeat.

Procedure: Catheter Ablation
Catheter ablation is a procedure that uses radiofrequency energy to destroy a small area of heart tissue that is causing rapid and irregular heartbeats. Destroying this tissue helps restore the heart's regular rhythm.

Active Comparator: ICD Only
Patient will receive an implantable cardioverter defibrillator (ICD) and standard medical management.
Device: Implantable Cardioverter Defibrillator (ICD)
An ICD is a battery-powered device placed under the skin that keeps track of heart rate. Thin wires connect the ICD to the heart. If an abnormal heart rhythm is detected, the device will deliver an electric shock to restore a normal heartbeat.

Active Comparator: Ablation Only (Registry)
The registry will enroll patients who refuse an implantable cardioverter defibrillator (ICD) and are thus not randomized. This arm will assess the efficacy of catheter ablation in the absence of background ICD therapy.
Procedure: Catheter Ablation
Catheter ablation is a procedure that uses radiofrequency energy to destroy a small area of heart tissue that is causing rapid and irregular heartbeats. Destroying this tissue helps restore the heart's regular rhythm.




Primary Outcome Measures :
  1. Freedom from recurrent VT, cardiovascular rehospitalization, and all-cause mortality [ Time Frame: 2 years ]
    The primary endpoint is a composite.


Secondary Outcome Measures :
  1. Freedom from recurrent VT [ Time Frame: 2 years ]
    Recurrent VT is defined as any appropriate ICD therapy (shock or ATP) or documented sustained monomorphic VT >30 seconds.

  2. Freedom from cardiovascular rehospitalization [ Time Frame: 2 years ]
    Cardiovascular rehospitalization is defined as a hospital admission after the randomized procedure for heart failure, procedure-associated complication, or arrhythmia-related causes during the follow-up period.

  3. Freedom from all-cause mortality [ Time Frame: 2 years ]

Other Outcome Measures:
  1. Comparison of outcomes in ablation only registry with randomized patients [ Time Frame: 2 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient is receiving a new implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy device (CRT-D) implant that has study required programing capabilities and is appropriate for remote monitoring. Patient who has received the ICD / CRT-D within 90 days of enrollment can also be enrolled.
  • Patient who has a high risk of ICD shock as shown by documented Monomorphic VT (MMVT) by one or more of the following:

    • Spontaneous MMVT
    • Inducible MMVT during electrophysiology study,
    • Inducible MMVT during noninvasive programmed stimulation study *Inducible MMVT is defined as MMVT > 30 seconds or requiring electrical termination (ATP or cardioversion)
  • Patient has ejection fraction < 50% or right ventricular dysfunction
  • Patient has a cardiomyopathy with structural heart disease of any cause

Exclusion Criteria:

  • Any history of debilitating stroke with neurologic deficit
  • ST-segment elevation myocardial infarction or previous cardiac surgery within 60 days prior to enrollment
  • Patient is pregnant or nursing
  • Patient has chronic New York Heart Association (NYHA) class IV heart failure
  • Patient has incessant VT necessitating immediate treatment
  • Patient has ventricular tachycardia/ventricular fibrillation thought to be from channelopathies
  • Limited life expectancy (less than one year)
  • Patient has current class IV angina
  • Recent coronary artery bypass graft or percutaneous coronary intervention (< 45 days)
  • Patient is currently participating in another investigational drug or device study
  • Known presence of intracardiac thrombi
  • Prosthetic mitral or aortic valve or mitral or aortic valvular heart disease requiring immediate surgical intervention
  • Major contraindication to anticoagulation therapy or coagulation disorder
  • Left Ventricular Ejection Fraction < 15%
  • Patient has had a previous ablation procedure for VT, excluding remote (> 3 months) outflow tract tachycardia
  • Patient has glomerular filtration rate (GFR) < 30 mL/min/1.73m2
  • Patient has peripheral vascular disease that precludes left ventricular access
  • Patient is thought to have idiopathic outflow VT as only VT
  • Patient has a premature ventricular contraction (PVC) or VT induced cardiomyopathy that is expected to resolve with ablation and will not require an ICD
  • Patient has reversible cause of VT
  • Patient does not meet criteria for ICD or CRT-D

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02848781


Contacts
Layout table for location contacts
Contact: Roderick Tung, MD 773-834-0455 rodericktung@uchicago.edu

Locations
Layout table for location information
China
Fuwai Cardiovascular Hospital Recruiting
Beijing, China
Contact: Yao Yan, MD         
Huaxi Hospital Recruiting
Chengdu, China
Contact: Jiang Jian, MD         
Guangdong General Hospital Recruiting
Guangzhou, China
Contact: Shulin Wu, MD         
Sir Run Run Shaw Hospital Recruiting
Hangzhou, China
Contact: Chenyang Jiang, MD         
Nanjing First Affiliated Hospital Recruiting
Nanjing, China
Contact: Minglong Chen, MD         
PLA Shenyang General Hospital Not yet recruiting
Shenyang, China
Contact: Zulu Wang, MD, PhD         
Japan
Dokkyo Medical University, Saitama Medical Center Recruiting
Saitama, Japan
Contact: Shiro Nakahara, MD, PhD         
Kyorin University Hospital Recruiting
Tokyo, Japan
Contact: Akiko Ueda, MD, PhD         
Contact: Kyoko Soejima, MD         
Tsukuba University Recruiting
Tsukuba, Japan
Contact: Akihiko Nogami, MD, PhD         
Korea, Republic of
Korea University Recruiting
Seoul, Korea, Republic of
Contact: Young Hoon Kim, MD, PhD         
Taiwan
Taipei Veterans General Hospital Recruiting
Taipei, Taiwan
Contact: Shih-Ann Chen, MD         
Sponsors and Collaborators
University of Chicago
Abbott Medical Devices
Investigators
Layout table for investigator information
Study Director: Roderick Tung, MD University of Chicago

Layout table for additonal information
Responsible Party: University of Chicago
ClinicalTrials.gov Identifier: NCT02848781     History of Changes
Other Study ID Numbers: IRB15-1739
First Posted: July 28, 2016    Key Record Dates
Last Update Posted: June 13, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by University of Chicago:
Sudden Cardiac Death
ICD Therapy
VT Ablation
Additional relevant MeSH terms:
Layout table for MeSH terms
Tachycardia
Tachycardia, Ventricular
Death, Sudden, Cardiac
Death
Pathologic Processes
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Cardiac Conduction System Disease
Heart Arrest
Death, Sudden